Abstract
Background: Mitotic kinesins are attractive targets in cancer chemotherapy. A large number of small-molecule inhibitors of kinesin spindle protein (KSP) and centromere-associated protein E (CENP-E) have been discovered. Objective: To estimate the therapeutic potential of mitotic kinesin inhibitors. Methods: We comprehensively summarized and analysed the trend among recent patents and conducted a literature review of clinical trials performed since July 2004. Results/conclusion: More than 80 patent applications have been made, spanning a wide range of structural diversity. Five KSP inhibitors and one CENP-E inhibitor have advanced to the early clinical stage, and some of the results for these clinical trials have been disclosed. The therapeutic potential for mitotic kinesin inhibitors is likely to become obvious within the next few years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
